🔴 We are now live with an insightful presentation by Dr. Remond J.A. Fijneman, Senior Researcher at The Netherlands Cancer Institute (NKI), Amsterdam, exploring the expanding role of circulating tumor DNA (ctDNA) in transforming colorectal cancer management.
Presentation: ctDNA Clinical Applications Along the Colorectal Cancer Patient Journey
During this session, Dr. Fijneman is highlighting how ctDNA-based liquid biopsy is reshaping clinical decision-making across every stage of the colorectal cancer journey. From early detection and risk assessment to minimal residual disease (MRD) evaluation, treatment monitoring, and early relapse detection, liquid biopsy is enabling more precise, personalized, and minimally invasive cancer care.
Drawing on his extensive translational research, Dr. Fijneman is demonstrating how ctDNA technologies are bridging laboratory innovation with real-world clinical practice, providing clinicians with powerful tools to improve patient outcomes and optimize treatment strategies.
This presentation offers valuable insights into one of the fastest-growing applications of precision oncology and showcases how liquid biopsy continues to revolutionize cancer diagnostics and disease management.
We sincerely thank Dr. Remond J.A. Fijneman for sharing his expertise and all participants joining us from around the world for making this symposium a vibrant platform for scientific collaboration and innovation.
This conference is organized by Impact Research Communications (IRC)
More info: https://liquidbio.ircconferences.net/ | Advances in Liquid Biopsy
